ESTRO 35 2016 S333 ________________________________________________________________________________ the GTV was undertaken on the images to quantify entropy, uniformity, mean grey-level intensity, kurtosis, standard deviation of histogram and skewness for fine to coarse textures (filters: 0.0-6.0).
Conclusion :
Normal 0 false false false EN-GB JA X-NONE We have shown using a 10% sample of the overall database available that CTimage heterogeneity factors are associated with PFS and OS for patients frommultiple centres. Preliminary results therefore suggest that in the future itmay be possible to make clinical treatment decisions based on the CT imageheterogeneity of a tumour volume. This will be confirmed by completing analysison the whole SCOPE 1 database. 
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Purpose or Objective:
To evaluate the feasibility and clinical results of stereotactic body radiation therapy (SBRT) in the treatment of hepatocellular carcinoma (HCC) in patients unsuitable or failing to standard loco-regional therapies.
Material and Methods:
Patients with < 3 inoperable HCC lesions with < 6 cm diameter were treated with SBRT. Prescription dose was adapted according to tumor size and global liver function and comprised 48-36 Gy in 3 fractions or 40 Gy in 5 fractions (prescribed on 80 % isodose). Primary endpoint included in-field (LC) local control and toxicity. Secondary endpoints were overall (OS), cancer-specific (CSS) and progression-free survival (PFS).
Results: 82 patients with 120 HCC lesions were treated. Median age was 70 (range 44-90). Most of the patients had Child-Pugh A5-A6 cirrhosis (80.4%), Barcelona Clinic Liver Cancer classification 0-A-B (93%). Median lesion size was 22 mm (range 7-120 mm). Most lesion were in the left lobe (65%). In most patients SBRT was the first local treatment (82%). Up to 7% of patients had portal vein thrombosis. Median observation time was 14 months. Actuarial 1-year LC, PFS, CSS and OS were 76.7% (95%CI:40-92.5%), 13.5% (95%CI:4.9-26-4), 92.1% (95%CI:81.8-96.7%) and 78% (95%CI:66.4-86%), respectively. Up to 18 patients (22%) experienced G3-G4 acute toxicity and 1 case of G5 toxicity was reported. Four cases of classical Radiation-induced liver disease (RILD) were reported, while 21 patients experienced a modification of Child-Pugh classification (25%), mostly of 2-3 points. On multivariate analysis, no factors were predictive for LC while initial Child-Pugh class and > 2 points Child-Pugh classification modification predicted for OS and CSS.
Conclusion: SBRT is a safe and effective treatment option for inoperable HCC, with acceptable LC rate and toxicity profile. Limiting toxic events may have prognostic significance. 
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